In particular, ibrutinib is an orally administered first-in-class covalent inhibitor of Bruton’s tyrosine kinase (BTK) that has been approved for treatment of CLL both in first-line and relapsed disease (Byrd et al., 2013; Farooqui et al., 2015). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.